A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
|Videos|April 10, 2013
Dr. Landgren on Carfilzomib and Pomalidomide
Author(s)C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
Advertisement
Ola Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, comments on the use of carfilzomib and pomalidomide for the treatment of myeloma.
Landgren says that researchers and physicians in the field of myeloma are fortunate to have recently-approved treatments. Carfilzomib, a second-generation proteasome inhibitor, and pomalidomide, a third-generation immunomodulatory drug, are both oral agents and provide "hope and promise" for patients. Landgren anticipates the trend of developing oral drugs to continue.
Advertisement
Related to this article
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
The selective ROCK2 inhibitor TDI01 generated organ-wide responses in previously treated moderate-to-severe chronic graft-versus-host disease, with the 400-mg dose performing best.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Novel Analysis Reveals Millions of Life-Years Saved by Blood Cancer Treatments
5